EASD 2022: The Real-World Observational Prospective Study of Health Outcomes with Dula and Liraglutide in Type 2 Diabetes Patients (TROPHIES): 24-M Clinical Characteristics and Treatment Patterns
The abstract presents the clinical outcomes and treatment patterns in the Real-World Observational Prospective Study of Health Outcomes with Dulaglutide & Liraglutide in Type 2 Diabetes (T2D) Patients (TROPHIES) was a 24-month, non-comparative, study in adult patients with T2D initiating Dulaglutide (DU) or Liraglutide (LIRA) as their first injectable glucose-lowering treatment.
The study participants were adult patients with T2D who were initiated with a regimen of once-weekly DU (N=1,014) or once-daily LIRA (N=991). The assessment of HbA1c, body weight and treatment patterns were the outcomes. The study results demonstrated that most patients were initiated with DU (856/1,014) 1.5 mg/week and among 286 patients with a significant treatment change, 237 were still receiving 1.5 mg/week. In the LIRA group, most patients (809/991) initiated at the starting dose 0.6 mg/day; in 45% patients the dose was increased to 1.2 mg/day by Day 90; 17% of patients were already receiving 1.8 mg/day by Day 90. At the first significant treatment change 285/448 patients in the LIRA cohort were receiving 1.2 mg/day insulin was initiated by 79 and 97 patients in the DU and LIRA cohorts, respectively.
From the above results, it can be concluded that, both Dulaglutide and Liraglutide have clinically meaningful effectiveness on HbA1c and weight and this effect maintained over the 24-month study period, consistent with results of clinical trials.
Oral Presentation # 615 Session: SO 46 Incretins European Association for the Study of Diabetes (EASD) International Congress 2022, 19th – 23rd Sept. 2022, Stockholm
